Wealth Enhancement Advisory Services LLC Grows Position in Humana Inc. $HUM

Wealth Enhancement Advisory Services LLC raised its stake in shares of Humana Inc. (NYSE:HUM) by 287.5% during the 4th quarter, Holdings Channel.com reports. The fund owned 52,512 shares of the insurance provider’s stock after acquiring an additional 38,962 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Humana were worth $14,699,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Capital International Investors purchased a new position in Humana during the third quarter worth about $707,670,000. Massachusetts Financial Services Co. MA increased its stake in Humana by 273.2% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,488,261 shares of the insurance provider’s stock valued at $907,541,000 after buying an additional 2,553,509 shares during the last quarter. Norges Bank purchased a new stake in Humana in the 2nd quarter valued at about $397,079,000. Bank of New York Mellon Corp lifted its position in shares of Humana by 161.5% during the 3rd quarter. Bank of New York Mellon Corp now owns 1,717,767 shares of the insurance provider’s stock worth $446,911,000 after buying an additional 1,060,767 shares in the last quarter. Finally, Dodge & Cox lifted its position in shares of Humana by 5.6% during the 2nd quarter. Dodge & Cox now owns 11,352,920 shares of the insurance provider’s stock worth $2,775,562,000 after buying an additional 597,705 shares in the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Trading Up 1.1%

Shares of HUM stock opened at $174.05 on Thursday. The stock has a market capitalization of $20.90 billion, a price-to-earnings ratio of 17.72, a PEG ratio of 1.84 and a beta of 0.44. The company’s fifty day simple moving average is $195.99 and its two-hundred day simple moving average is $240.31. Humana Inc. has a 1 year low of $163.11 and a 1 year high of $315.35. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.00 and a quick ratio of 2.00.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) EPS for the quarter, topping analysts’ consensus estimates of ($4.01) by $0.05. The firm had revenue of $32.64 billion during the quarter, compared to analyst estimates of $32.08 billion. Humana had a return on equity of 11.43% and a net margin of 0.92%.The business’s revenue for the quarter was up 11.3% on a year-over-year basis. During the same period last year, the company earned ($2.16) earnings per share. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. As a group, analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, April 24th. Shareholders of record on Friday, March 27th will be paid a $0.885 dividend. The ex-dividend date is Friday, March 27th. This represents a $3.54 annualized dividend and a yield of 2.0%. Humana’s dividend payout ratio (DPR) is currently 36.05%.

Insider Buying and Selling

In related news, insider Sanjay K. Shetty bought 810 shares of Humana stock in a transaction on Monday, February 23rd. The stock was acquired at an average price of $185.21 per share, with a total value of $150,020.10. Following the acquisition, the insider directly owned 11,657 shares of the company’s stock, valued at $2,158,992.97. This represents a 7.47% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.20% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. KeyCorp reaffirmed a “sector weight” rating on shares of Humana in a report on Friday, December 12th. JPMorgan Chase & Co. dropped their price target on Humana from $274.00 to $180.00 and set a “neutral” rating on the stock in a report on Friday, February 13th. Cantor Fitzgerald cut their price objective on Humana from $290.00 to $201.00 and set a “neutral” rating on the stock in a research report on Thursday, February 12th. Evercore reduced their price objective on Humana from $260.00 to $180.00 in a research note on Thursday, February 12th. Finally, Robert W. Baird decreased their target price on Humana from $280.00 to $264.00 and set a “neutral” rating for the company in a research report on Thursday, December 11th. Seven research analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $225.48.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.